ORIC PharmaceuticalsFRA:4TZ -2.77%32 PB Ratio is 2.63 as of Jul. 11, 2026. GuruFocus rates FRA:4TZ with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,227 Biotechnology companies, ORIC Pharmaceuticals ranks better than 52.73% on this metric.
The historical rank and industry rank for ORIC Pharmaceuticals's PB Ratio or its related term are showing as below:
FRA:4TZ'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 2.72
Current: 2.64
During the past 8 years, ORIC Pharmaceuticals's highest PB Ratio was 2.72. The lowest was 0.00. And the median was 0.00.
FRA:4TZ's PB Ratio is ranked better than 52.73% of 1227
companies
in the Biotechnology industry
Industry Median: 2.95
vs FRA:4TZ: 2.64
During the past 12 months, ORIC Pharmaceuticals's average Book Value Per Share Growth Rate was 14.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -7.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -15.40% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of ORIC Pharmaceuticals was -7.50% per year. The lowest was -20.90% per year. And the median was -19.70% per year.
Back to Basics: PB Ratio
ORIC Pharmaceuticals (FRA:4TZ) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
ORIC Pharmaceuticals PB Ratio Related Terms
ORIC Pharmaceuticals PB Ratio Historical Data
* Premium members only.
The historical data trend for ORIC Pharmaceuticals's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ORIC Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ORIC Pharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ORIC Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where ORIC Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
ORIC Pharmaceuticals (FRA:4TZ) has a PB Ratio of 2.63 as of Jul. 11, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ORIC Pharmaceuticals and its competitors. According to the industry distribution chart, ORIC Pharmaceuticals ranks #580 out of 1227 companies in the Biotechnology industry, placing it in the top 47.3%.
Is ORIC Pharmaceuticals' PB Ratio too high?
ORIC Pharmaceuticals' current PB Ratio is 2.63. The Biotechnology industry median PB Ratio is 2.95. ORIC Pharmaceuticals' value of 2.63 is 10.8% below this industry median. Based on the distribution chart, ORIC Pharmaceuticals ranks #580 out of 1227 companies in the Biotechnology industry, which is above the industry midpoint. Overall, ORIC Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does ORIC Pharmaceuticals' PB Ratio compare to DRTS and OLMA?
According to the Biotechnology industry distribution chart, ORIC Pharmaceuticals ranks #580 out of 1227 companies for PB Ratio. This puts ORIC Pharmaceuticals in the upper half of its industry. The industry median PB Ratio is 2.95. ORIC Pharmaceuticals' value of 2.63 is 10.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.95, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ORIC Pharmaceuticals's current PB Ratio of 2.63 is 10.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ORIC Pharmaceuticals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ORIC Pharmaceuticals's current PB Ratio is 2.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ORIC Pharmaceuticals stock overvalued right now?
ORIC Pharmaceuticals (FRA:4TZ) has a current PB Ratio of 2.63. The current PB Ratio is 2.63 and 10.8% below the Biotechnology industry median of 2.95. ORIC Pharmaceuticals' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For ORIC Pharmaceuticals (FRA:4TZ), the current PB Ratio is 2.63 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
32GF Score
Get the complete analysis for FRA:4TZ
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4TZ has been successfully added to your 
